Ann Liver Transplant.  2024 May;4(1):10-15. 10.52604/alt.24.0006.

Surveillance and management of de novo malignancy after liver transplantation

• Kang WH

• KMID: 2560936
• DOI: http://doi.org/10.52604/alt.24.0006

Abstract

Liver transplantation (LT) has significantly improved long-term survival rates, but recipients face increased risks of de novo malignancy (DNM) due to immunosuppression. DNM patterns differ worldwide, with post-transplant lymphoproliferative disorder common in Western countries, while South Korea sees more gastric and colorectal cancers. Risk factors include immunosuppressive drugs, underlying conditions, and lifestyle factors. Screening strategies should be tailored to regional DNM patterns, with regular surveillance crucial for early detection and management. Minimizing immunosuppressant usage and prompt local treatment upon DNM detection offer favorable outcomes for LT recipients.

Keyword

Liver transplantation; De novo malignancy; Screening strategy; Management

Reference

1. Kim M, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, et al. 2022; Twenty-year longitudinal follow-up after liver transplantation: a single-center experience with 251 consecutive patients. Korean J Transplant. 36:45–53. DOI: 10.4285/kjt.21.0031. PMID: 35769427. PMCID: PMC9235526.

2. Åberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen A, et al. 2015; Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology. 61:668–677. DOI: 10.1002/hep.27538. PMID: 25266201.

3. Jiang Y, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. 2008; Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl. 14:1588–1597. DOI: 10.1002/lt.21554. PMID: 18975293.

4. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. 2011; Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 306:1891–1901. DOI: 10.1001/jama.2011.1592. PMID: 22045767. PMCID: PMC3310893.

5. Taborelli M, Piselli P, Ettorre GM, Baccarani U, Burra P, Lauro A, et al. 2019; Survival after the diagnosis of de novo malignancy in liver transplant recipients. Int J Cancer. 144:232–239. DOI: 10.1002/ijc.31782. PMID: 30091809.

6. Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, et al. 2012; De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transplant Proc. 44:802–805. DOI: 10.1016/j.transproceed.2012.01.027. PMID: 22483500.

7. Kim S, Rovgaliyev B, Lee JM, Lee KW, Hong SK, Cho JH, et al. 2021; Clinical significance of de novo malignancy after liver transplant: a single-center study. Transplant Proc. 53:200–206. DOI: 10.1016/j.transproceed.2020.02.148. PMID: 32409224.

8. Sérée O, Altieri M, Guillaume E, De Mil R, Lobbedez T, Robinson P, et al. 2018; Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study on 11,226 patients. Liver Transpl. 24:1425–1436. DOI: 10.1002/lt.25310. PMID: 30021061.

9. Shin M, Moon HH, Kim JM, Park JB, Kwon CH, Kim SJ, et al. 2013; Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center. Transplant Proc. 45:3019–3023. DOI: 10.1016/j.transproceed.2013.08.061. PMID: 24157026.

10. Kaneko J, Sugawara Y, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, et al. 2013; De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study. Transplantation. 95:1142–1147. DOI: 10.1097/TP.0b013e318288ca83. PMID: 23572128.

11. Gao PJ, Gao J, Li Z, Hu ZP, Zhu JY. 2015; De novo malignancy after liver transplantation: a single-center experience of 14 cases. Ann Surg Treat Res. 88:222–228. DOI: 10.4174/astr.2015.88.4.222. PMID: 25844357. PMCID: PMC4384282.

12. Park B, Yoon J, Choi D, Kim HJ, Jung YK, Kwon OJ, et al. 2019; De novo cancer incidence after kidney and liver transplantation: results from a nationwide population based data. Sci Rep. 9:17202. DOI: 10.1038/s41598-019-53163-9. PMID: 31748582. PMCID: PMC6868238.

13. Haider M, Bapatla A, Ismail R, Chaudhary AJ, Iqbal S, Haider SM. 2022; The spectrum of malignant neoplasms among liver transplant recipients: sociodemographic factors, mortality, and hospital burden. Int J Med Sci. 19:299–309. DOI: 10.7150/ijms.66533. PMID: 35165515. PMCID: PMC8795812.

14. Colmenero J, Tabrizian P, Bhangui P, Pinato DJ, Rodríguez-Perálvarez ML, Sapisochin G, et al. 2022; De novo malignancy after liver transplantation: risk assessment, prevention, and management-guidelines from the ILTS-SETH Consensus Conference. Transplantation. 106:e30–e45. DOI: 10.1097/TP.0000000000003998. PMID: 34905760.

15. Dierickx D, Habermann TM. 2018; Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 378:549–562. DOI: 10.1056/NEJMra1702693. PMID: 29414277.

16. Gong CS, Yoo MW, Kim BS, Hwang S, Kim KH, Yook JH, et al. 2016; De novo gastric cancer after liver transplantation. Ann Transplant. 21:386–391. DOI: 10.12659/AOT.897595. PMID: 27334929.

17. Kim S, Lee HJ, Alzahrani F, Kim J, Kim SH, Kim S, et al. 2023; Clinical outcomes of gastric cancer surgery after liver transplantation. Ann Surg Treat Res. 104:101–108. DOI: 10.4174/astr.2023.104.2.101. PMID: 36816738. PMCID: PMC9929436.

18. Ko CS, Jheong JH, Jeong SA, Kim BS, Yook JH, Kim BS, et al. 2023; Safety evaluation of curative gastrectomy for gastric cancer patients who underwent liver transplantation: a comparative study with conventional gastrectomy for gastric cancer patients. World J Surg Oncol. 21:145. DOI: 10.1186/s12957-023-03028-3. PMID: 37165421. PMCID: PMC10173655.

19. Fu C, Li X, Chen Y, Long X, Liu K. 2023; Lung cancer incidences after liver transplantation: a systematic review and meta-analysis. Cancer Med. 12:16119–16128. DOI: 10.1002/cam4.6265. PMID: 37351559. PMCID: PMC10469810.

20. Kocher F, Finkenstedt A, Fiegl M, Graziadei I, Gamerith G, Oberaigner W, et al. 2015; Liver transplantation-associated lung cancer: comparison of clinical parameters and outcomes. Clin Lung Cancer. 16:e75–e81. DOI: 10.1016/j.cllc.2015.02.003. PMID: 25783479.

21. Rompianesi G, Ravikumar R, Jose S, Allison M, Athale A, Creamer F, et al. 2019; Incidence and outcome of colorectal cancer in liver transplant recipients: a national, multicentre analysis on 8115 patients. Liver Int. 39:353–360. DOI: 10.1111/liv.13947. PMID: 30129181.

22. Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. 2017; Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis. Gastrointest Endosc. 86:93–104.e5. DOI: 10.1016/j.gie.2016.12.009. PMID: 28011280.

23. Kim M, Kim CW, Hwang S, Kim YH, Lee JL, Yoon YS, et al. 2021; Characteristics and prognosis of colorectal cancer after liver or kidney transplantation. World J Surg. 45:3206–3213. DOI: 10.1007/s00268-021-06219-9. PMID: 34235562.

24. Jung DH, Hwang S, Song GW, Ahn CS, Moon DB, Ha TY, et al. 2016; Survival benefit of early cancer detection through regular endoscopic screening for de novo gastric and colorectal cancers in Korean liver transplant recipients. Transplant Proc. 48:145–151. DOI: 10.1016/j.transproceed.2015.12.003. PMID: 26915860.

25. Kim DS, Yoon YI, Kim BK, Choudhury A, Kulkarni A, Park JY, et al. 2024; Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation. Hepatol Int. 18:299–383. DOI: 10.1007/s12072-023-10629-3. PMID: 38416312.